No protective role of Helicobacter pylori in the pathogenesis of reflux esophagitis in patients with duodenal or benign gastric ulcer in Korea
- PMID: 11768266
- DOI: 10.1023/a:1012783630913
No protective role of Helicobacter pylori in the pathogenesis of reflux esophagitis in patients with duodenal or benign gastric ulcer in Korea
Abstract
Little is known about the relationship between H. pylori infection and reflux esophagitis. To evaluate whether or not H. pylori plays a protective role in the pathogenesis of reflux esophagitis, the prevalence rates of reflux esophagitis depending on H. pylori status in consecutively diagnosed duodenal ulcer or benign gastric ulcer patients were evaluated. In addition, the incidence rates of reflux esophagitis depending on H. pylori status were evaluated for those patients who received follow-up endoscopy at least 6 months after eradication treatment. The prevalence rates of reflux esophagitis were 8.0% (2 patients) in the 25 H. pylori-negative duodenal ulcer group patients and 6.5% (36 patients) in the 555 H. pylori-positive duodenal ulcer group patients, and there was no statistical difference. Similarly, that of gastric ulcer patients was 9.4% (32 patients) in the 340 H. pylori-positive group patients, slightly higher than that in the 41 H. pylori-negative group patients 4.9% (2 patients), but without statistical significance. After eradication treatment the reflux esophagitis incidence rates were 2.5% (2 patients) in the 81 H. pylori-eradicated duodenal ulcer group patients and 7.7% (3 patients) in the 39 noneradicated duodenal ulcer group patients, and there was no statistical difference. Similarly, those of gastric ulcer patients were 6.8% (3 patients) in the 44 H. pylori-eradicated and 8.7% (2 patients) in the 23 noneradicated group patients again without statistical difference. These results suggest that H. pylori does not play a protective role in the pathogenesis of reflux esophagitis in patients with duodenal or gastric ulcer in Korea.
Similar articles
-
Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease -- results from a randomized trial programme.Aliment Pharmacol Ther. 2002 Aug;16(8):1431-42. doi: 10.1046/j.1365-2036.2002.01285.x. Aliment Pharmacol Ther. 2002. PMID: 12182742 Clinical Trial.
-
Increased body mass index after H. pylori eradication for duodenal ulcer predisposes to erosive reflux esophagitis.J Clin Gastroenterol. 2009 Sep;43(8):705-10. doi: 10.1097/MCG.0b013e3181948c45. J Clin Gastroenterol. 2009. PMID: 19398924
-
De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study.Medicina (Kaunas). 2010;46(7):454-9. Medicina (Kaunas). 2010. PMID: 20966617
-
H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications.Helicobacter. 1998 Sep;3(3):145-51. doi: 10.1046/j.1523-5378.1998.08031.x. Helicobacter. 1998. PMID: 9731983 Review.
-
[Role of Helicobacter pylori in reflux esophagitis].Nihon Geka Gakkai Zasshi. 1997 Nov;98(11):932-5. Nihon Geka Gakkai Zasshi. 1997. PMID: 9488977 Review. Japanese.
Cited by
-
Eradication of Helicobacter Pylori Infections and GERD: A systematic review and meta-analysis.Turk J Gastroenterol. 2020 Dec;31(12):853-859. doi: 10.5152/tjg.2020.19699. Turk J Gastroenterol. 2020. PMID: 33625997 Free PMC article.
-
Endoscopic Reflux Esophagitis and Reflux-Related Symptoms after Helicobacter pylori Eradication Therapy: Meta-Analysis.J Clin Med. 2020 Sep 18;9(9):3007. doi: 10.3390/jcm9093007. J Clin Med. 2020. PMID: 32961949 Free PMC article.
-
Systematic investigation of gastrointestinal diseases in China (SILC): validation of survey methodology.BMC Gastroenterol. 2009 Nov 19;9:86. doi: 10.1186/1471-230X-9-86. BMC Gastroenterol. 2009. PMID: 19925662 Free PMC article. Clinical Trial.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical